Fierce Biotech
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio
Johnson & Johnson has paid $1 billion upfront to buy itself a degrader antibody conjugate platform via the acquisition of Firefly Bio.
Medical Technology · page 24
Devices, digital health, and the technology changing how care is delivered.
Fierce Biotech
Incyte inks $2B deal to add Star unit to late-phase constellation and challenge Takeda
Incyte has struck a deal to buy a Star Therapeutics subsidiary for $1.25 billion upfront. The takeover, the biggest bet of Bill Meury’s time as CEO, covers a late-phase bleeding disorder drug candidate that could support Incyte’s ambition to grow through the loss of patent protection for Jakafi in 2028.
Fierce Biotech
GSK pledges £44.5M in near term for UK biotech to explore cause of liver fibrosis regression
GSK’s latest hepatology partnership is posing a less-asked question—how do you encourage the regression of patients’ liver fibrosis?
Fierce Biotech
How integrated strategy is reshaping biopharma growth
RevHealth CEO Ben Beckley shares how integrated teams are helping biopharma organizations align strategy, break down silos and drive stronger commercial impact.
Fierce Biotech
Managing complexity across biopharma modalities
SK pharmteco CEO Joerg Ahlgrimm discusses complexity, global pressure and drug development speed.
Fierce Biotech
How AI is reshaping biopharma decision-making
AI is accelerating discovery, but only when paired with expert insight and trusted data. Hear how leaders are rethinking decision-making in biopharma.
Fierce Biotech
Could engaging the immune system improve AML outcomes?
With unmet need still high in AML, new approaches are exploring whether engaging immune responses could help improve long-term disease control.
Fierce Biotech
How Unlearn is building a scientific intelligence layer for clinical development
Unlearn founder and head of AI, Aaron Smith, on how digital twins are moving from trial simulation into the full chain of decisions sponsors make — and what regulators need to see along the way.
Fierce Biotech
Why Execution Excellence Now Defines Biopharma Winners
Strategy matters—but execution separates leaders. Hear how top biopharma teams translate strategy into results.
Fierce Biotech
Why AI is changing clinical development
PhaseV CEO Raviv Pryluk explains how AI is reshaping trial design and execution.
Fierce Biotech
Biotech value creation at an inflection point
Capital is tighter and expectations are higher. Hear how biotech leaders must rethink value, evidence and deal readiness in 2026.
Fierce Biotech
Biopharma IPOs: Timing, capital and staying flexible
Regulatory shifts, tight capital and volatile IPO windows are reshaping biopharma strategy. Hear how leaders are adapting.
Fierce Biotech
Biopharma moves to reduce development risk earlier than ever
Tighter capital, higher expectations and evolving regulatory frameworks are reshaping drug development strategy. Parexel leaders explain how companies are adapting.
Fierce Biotech
Executive Interviews at Fierce Biotech Week 2026
Discover how these trailblazers are accelerating breakthroughs, forging impactful partnerships, and redefining what’s possible in life sciences. Access the exclusive interviews below to get inspired and stay ahead of the curve.
Fierce Biotech
ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect
As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche helped get the show rolling with a deep dive into their amylin analog, petrelintide.
Fierce Biotech
ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes
Even as Zepbound fires on all cylinders and Foundayo gets off to the races in the oral market, Eli Lilly is keenly aware that the one-size-fits-all approach to obesity and diabetes treatment pioneered by early GLP-1s will soon be obsolete.
Fierce Biotech
ADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy
On the heels of a strong showing for the drug earlier this year, Pfizer is padding the case for the GLP-1 receptor agonist it picked up in its $10 billion purchase of obesity biotech Metsera.
Fierce Biotech
‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs
When it comes to turning T-cell therapies toward autoimmune diseases, CAR-Ts have been leading the way. But another red-hot modality is also beginning to show potential in the clinic.
Fierce Biotech
Cancer biotech Parabilis ups IPO plans to potentially record-setting $637M
Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, with a whopping $625 million, Parabilis Medicines has upsized its own IPO plans with the potential to eclipse that record.
Fierce Biotech
Lilly moves deeper into Alzheimer’s research with AlzeCure licensing deal
Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease from AlzeCure Pharma for up to $1 billion biobucks.
Fierce Biotech
CeQur nabs $100M series E to fuel insulin patch commercialization
Swiss medtech CeQur has raised $100 million in a series E funding round for what it called its “most ambitious phase of commercial growth.”
Fierce Biotech
Roche sticks with €600M diagnostics investment in Germany but warns of future risk
As news hit last week that Eli Lilly and Boehringer Ingelheim are cutting investments in Germany, Roche said it will not be following suit—for now.
Fierce Biotech
The new standard for trusted AI in biopharma
As costs climb, capital tightens and AI enthusiasm accelerates, biopharma leaders are rethinking how better decisions get made.
Fierce Biotech
GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer
GSK has struck a deal to buy Nuvalent for $10.6 billion, securing two near-approval cancer therapies that could challenge products from Roche, Pfizer and other drugmakers.